Aligos Therapeutics Presses Capital Raise Button

by Vandana Singh, Benzinga Editor

June 29, 2021 8:52 AM | 1 min read |

Aligos Therapeutics Inc ALGS commenced an underwritten public offering of 4 million shares of common stock.
Underwriters can purchase up to an additional 600k shares.
J.P. Morgan, Jefferies, and Piper Sandler are acting as the joint book-running managers for the offering.
Cantor is acting as a lead manager for the offering.
The proceeds will be used to fund the clinical development of STOPS candidates and R&D activities for siRNA and NASH THR-ß candidates.
See the offering prospectus here.
Price Action: ALGS shares are down 7.07% at $22.07 during the premarket session on the last check Tuesday.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.